0.38
-0.0201(-4.96%)
Currency In USD
Address
3204–4464 Markham Street
Victoria, BC V8Z 7X8
Canada
Phone
250-483-0308
Sector
Healthcare
Industry
Biotechnology
Employees
72
First IPO Date
January 07, 2002
Name | Title | Pay | Year Born |
Dr. Jennifer Lynne Bath Ph.D. | Chief Executive Officer, President & Non-Independent Director | 696,833 | N/A |
Ms. Kari Graber | Vice President of Commercial Services | 189,640 | N/A |
Dr. Ilse Roodink | Chief Scientific Officer & Interim General Manager of IPA Europe, Oss | 191,948 | N/A |
Mr. Joseph Scheffler | Interim Chief Financial Officer | 0 | N/A |
ImmunoPrecise Antibodies Ltd., together with its subsidiaries, engages in antibody production and provision of related services in the United States, Canada, Europe, Australia, and internationally. The company offers a range of antibodies, enzymes, enzyme activity assays, arthritis animal products, proteins, deiminated proteins, organoid growth factors, and hybridoma products for research purposes. Its contract research organization services include custom antigen modeling, design, and manufacturing; B cell sorting, screening, and sequencing; custom, immune, and naive phage display production and screening; transgenic animals and multi-species antibody discovery; bi-specific, tri-specific, VHH, and VNAR (shark) antibody manufacturing; DNA cloning, protein and antibody downstream processing; antibody characterization on label-free biosensors and antibody engineering; transient and stable cell line generation; antibody optimization and humanization; hybridoma production with multiplexed, high-throughput screening, and clone-picking; and cryopreservation. The company has research collaboration agreements with Pierre Fabre S.A for antibody discovery; and Elektrofi, Inc. to explore a high-concentration formulation of COVID-19 antibody cocktail, PolyTope TATX-03. ImmunoPrecise Antibodies Ltd. was incorporated in 1983 and is based in Victoria, Canada.